Antibody Drug Conjugate Drug Market Growth, Top Players, and Forecast by 2031

Historic Data: 2021-2023   |   Base Year: 2024   |   Forecast Period: 2025-2031

Coverage: Antibody Drug Conjugate Drug Market covers analysis By Product (Adcertis, Kadcyla); Technology (ImmunoGen technology, Seattle Genetics technology, Immunomedics technology); End User (Hospitals, Specialized Cancer Centers, Academic Research Institutes, Biotechnology Companies, Biopharmaceutical Companies, Others) , and Geography (North America, Europe, Asia Pacific, and South and Central America)

  • Report Code : TIPRE00016840
  • Category : Life Sciences
  • Status : Upcoming
  • No. of Pages : 150
Buy Now

MARKET INTRODUCTION



Antibody Drug Conjugate Drug is the class of highly potent biopharmaceutical anticancer agents. Antibody drug conjugates have monoclonal antibodies which targets on the specific target site of tumor to destroy cancer cells. Antibody drug conjugates having very potent anti-cancer agents which are linked each other's via a chemical linkage. Antibody drug conjugates have a wide application in oncology and hematology.

MARKET DYNAMICS



The key market drivers for Antibody Drug Conjugate Drug Market Includes, rising prevalence of cancer patients globally especially several grades of lymphomas and solid tumor cancers. Moreover, high R&D investments by biopharmaceutical industries is also expected to boost market growth during the forecast period. Whereas, high cost of the therapy and possible cytotoxity and other side effects due to antibody drug conjugates may have negative impact on market growth during the forecast period.

MARKET SCOPE



The "Antibody Drug Conjugate Drug Market" is a specialized and in-depth study of the Pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Antibody Drug Conjugate Drug market with detailed market segmentation by product, technology and end user. The Antibody Drug Conjugate Drug Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Antibody Drug Conjugate Drug Market and offers key trends and opportunities in the market.

MARKET SEGMENTATION



The Antibody Drug Conjugate Drug Market is segmented on the basis of product, technology and end user. On the basis of product the market is segmented as, Adcertis, Kadcyla. On the basis of technology the market can be segmented as, immunogen technology, seattle genetics technology and immunomedics technology, And on the basis of end user the market is segmented as, hospitals, cancer centers, academic and research institutes, biopharmaceutical companies and others.

REGIONAL FRAMEWORK



The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Antibody Drug Conjugate Drug Market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Antibody Drug Conjugate Drug Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Antibody Drug Conjugate Drug Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Antibody Drug Conjugate Drug Market in these regions.

MARKET PLAYERS



The report covers key developments in the Antibody Drug Conjugate Drug Markets organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Antibody Drug Conjugate Drug Market are anticipated to have lucrative growth opportunities in the future with the rising demand for, Antibody Drug Conjugate Drug market in the global market. Below mentioned is the list of few companies engaged in the Antibody Drug Conjugate Drug Market.

The report also includes the profiles of key players in Antibody Drug Conjugate Drug Market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered financial information of last 3 years, key development in past five years.

  •   Genentech USA,Inc
  •   Seattle Genetics
  •   F. Hoffmann -La Roche Ltd
  •   Takeda Pharmaceuticals
  •   Pfizer, Inc
  •   AbbVie Inc
  •   Immunomedics
  •   ImmunoGen, Inc
  •   Lonza
  •   Creative Biolabs

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.

Antibody Drug Conjugate Drug Report Scope

Report Attribute Details
Market size in 2024 US$ XX million
Market Size by 2031 US$ XX Million
Global CAGR (2025 - 2031) XX%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Product
  • Adcertis
  • Kadcyla
By Technology
  • ImmunoGen technology
  • Seattle Genetics technology
  • Immunomedics technology
By End User
  • Hospitals
  • Specialized Cancer Centers
  • Academic Research Institutes
  • Biotechnology Companies
  • Biopharmaceutical Companies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Genentech USA, Inc
  • Seattle Genetics
  • F. Hoffmann-La Roche Ltd
  • Takeda Pharmaceuticals
  • Pfizer Inc
  • AbbVie Inc
  • Immunomedics
  • ImmunoGen Inc
  • Lonza
    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset
    antibody-drug-conjugate-drug-market-report-deliverables-img1
    antibody-drug-conjugate-drug-market-report-deliverables-img2
    Report Coverage

    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered

    Segment Covered

    This text is related
    to segments covered.

    Regional Scope

    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope

    Country Scope

    This text is related
    to country scope.

    Trends and growth analysis reports related to Life Sciences : READ MORE..   

    The List of Companies

    1. Genentech USA, Inc
    2. Seattle Genetics
    3. F. Hoffmann-La Roche Ltd
    4. Takeda Pharmaceuticals
    5. Pfizer Inc
    6. AbbVie Inc
    7. Immunomedics
    8. ImmunoGen Inc
    9. Lonza
    10. Creative Biolabs
    antibody-drug-conjugate-drug-market-cagr